Two re com bi nant hu man in ter feron-beta 1a phar ma ceu ti cal prep a ra tions Ab stract. Ob jec tives: Re com bi nant human in ter feron-beta (IFN-b) is a well-es tablished treat ment for mul ti ple scle ro sis (MS). The reg u la tory pro cess for mar ket ing au tho riza tion of biosimilars is cur rently un der de bate in cer tain coun tries. In the EU, EMEA has clearly de fined the pro cess in clud ing overarch ing and prod uct-spe cific guide lines, which in cludes clin i cal test ing. Biosimilarity needs to be based on com pa ra bil ity cri te ria, in clud ing at least mo lec u lar char ac ter iza tion, bi o log i cal ac tiv ity rel e vant for the ther a peu tic ef fect and rel a tive bioavailability ("bioequivalence"). In the case of such com plex dis eases as MS, where the ef fect of treat ment is not so di rectly mea sur able, in vi tro tools can pro vide ad di tional data to sup port com pa ra bil ity. Genomic microarrays as says might be use ful to com pare multisource biopharmaceuticals. The aim of the pres ent study was to com pare the pharmacodynamic genomic ef fects (in terms of transcriptional reg u la tion) of two recom bi nant hu man IFN-b-1a prep a ra tions on lym pho cytes of mul ti ple scle ro sis pa tients using a whole ge nome microarray as say. Methods: We per formed an ex vivo whole ge nome ex pres sion pro fil ing of the ef fect of two prepa ra tions of IFN-b1a on non-ad her ent mononu clears from five re laps ing-re mit ting MS pa tients an a lyz ing microarrays (CodeLink™ Hu man Whole Ge nome). Pa tients blood was drawn, PBMCs iso lated and cul tured in three dif fer ent con di tions: cul ture me dium (control), 1,000 U/ml of IFN-b1a (BLA-(STOFERON™, Bio Sidus) and 1,000 U/ml of IFN-b1a (REBIF™, Serono) RNA was puri fied from non-ad her ent cells (mostly lympho cytes), am pli fied and hy brid ized. Raw data were gen er ated by CodeLink™ pro prietary soft ware. Data nor mal iza tion, qual ity con trol and anal y sis of dif fer en tial gene expres sion be tween treat ments were done us ing lin ear model for microarray data. Func tional an no ta tion anal y sis of IFN-b1a MS treat ment tran scrip tion was done us ing DA VID. Results: Out of the ap prox i mately 45,000 hu man se quences ex am ined, no ev i dence of dif fer ential reg u la tion was found when both treatments were com pared (min i mum ad justed p-value > 0.999). The IFN-b1a ef fect dif feren tially reg u lated the ex pres sion of 868 genes. The ex pres sion of stan dard mark ers such as GTP cyclo hidro lase, MxA, and OAS isoenzymes A and B changed as a con sequence of the ac tion of IFN-b1a. Con clusions: This ex haus tive and highly sen si tive as say did not show dif fer ences in the genomic ex pres sion pro file of these two prod ucts under the as sayed ex per i men tal con di tions. These re sults sug gest that this tech nol ogy might be use ful for the ini tial com par i son of biosimilars, be ing part of a com pre hen sive com pa ra bil ity pro gram that in cludes clin i cal test ing.
Introduction
Mul ti ple scle ro sis (MS) is a chronic demyelinating dis ease that af fects the cen tral ner vous sys tem (CNS) [Hauser and Oksenberg 2006] . Af ter em pir i cal re search with clin i cal tri als, IFN-b has be come a well-estab lished treat ment for MS [Sibley and Group 1993] . This cytokine es sen tially acts through transcriptional reg u la tion; how ever, the rel evant genes in volved in its ther a peu tic ef fects have not been fully elu ci dated yet. The reg ula tory pro cess for mar ket ing au tho ri za tion of biosimilars is cur rently un der de bate. Biosimilarity needs to be based on com pa ra bil ity cri te ria, in clud ing at least mo lec u lar char acter iza tion, bi o log i cal ac tiv ity rel e vant for the ther a peu tic ef fect and rel a tive bioavailability ("bioequivalence"). In the case of such complex dis eases as MS, where the ef fect of treatment is not so di rectly measurable, in vitro tools can provide additional data to support com parability.
Guide lines have ad dressed this topic suggest ing that new tech nol o gies might be use ful to com pare multisource biopharmaceuticals and multidisciplinary stud ies are un der way in or der to stan dard ize cri te ria and plat forms. As an ex am ple, re cent guide lines from the Eu ropean Med i cines Agency (EMEA, Lon don) address this is sue and state that the use of genomic microarray de serves con sid er ation for the as sess ment of pharmacodynamic actions of this kind of prod ucts be cause of its abil ity to de tect mi nor changes in the bi o log ical re sponse to ac tive sub stances. Also the USA Food and Drug Ad min is tra tion (FDA) is car ry ing out a multidisciplinary pro ject called MAQC (Mi cro Ar ray Qual ity Con trol) to standard ize the use of this meth od ol ogy as a reg ula tory tool [Ji and Da vis 2006] . This study was per formed to com pare the genomic re sponse at gene ex pres sion lev els in duced by two sim i lar IFN-b1a for mu la tions: Blasto feron ® (Bio Sidus SA, Bue nos Ai res, Ar gen tina) and Rebif ® (Serono S.p.A, Bari, It aly).
Materials and methods

IFN-b1a phar ma ceu ti cal prep a ra tion
IFN-b1a is a re com bi nant glycosylated form of IFN-b struc tur ally in dis tin guish able from nat u ral IFN-b in its pri mary se quence and car bo hy drate con tent, ex pressed in Chinese ham ster ovary (CHO) cells [Knight and Fahey 1982, Utsumi et al. 1989 ]. The two prep a ra tions com pared of this ac tive in gre dient were Rebif® (Serono S.p.A, Bari, It aly; im ported by Serono Ar gen tina SA) and Blastoferon® (Bio Sidus SA, Bue nos Ai res, Ar gen tina), which was de signed as Rebif® biosimilar. Blastoferon® has been ap proved for com mer cial use by the Ar gen tin ean National Reg u la tory Agency (ANMAT) on April 2005 and has dem on strated equiv a lent bioavailability to Rebif ® af ter sub cu ta ne ous in jec tion (Di Girolamo et al., manu script in prep a ra tion). Pre-filled sy ringes of 12 MUI of both prod ucts were used in the ex per i ment (Blastoferon ® lot num ber F12-JE05-C and Rebif ® lot num ber L6784001B RBS 308049-B).
Patients
In vi tro whole ge nome ex pres sion pro filing of the ef fect of two prep a ra tions of IFNb1a was per formed on non-ad her ent mononuclear cells from 5 re laps ing-re mit ting multi ple scle ro sis pa tients (RRMS, 2 males, 3 females, aged from 15 to 54 years) us ing micro array anal y sis (CodeLink™ Hu man Whole Ge nome, GE Healthcare Bio sci ences Corp., Sunnyvale, CA, USA).
RRMS di ag no sis was made ac cord ing to es tab lished cri te ria [Mc Don ald et al. 2001] . Their ex panded dis abil ity sta tus scale (EDSS) score was be tween 0 and 8. Among the five patients, two were re ceiv ing IFN-b1a at the time of blood sam ple col lec tion, ex pe ri enc ing good clin i cal re sponse; one had re ceived IFN-b1a for 3 years un til one year be fore blood sam ple collec tion, when im muno modulatory treat ment was dis con tin ued be cause of lack of ef fi cacy; and the other two had never re ceived IFN-b1a. No pa tient had re ceived corticosteroid or immuno sup pres sive ther apy dur ing at least one month be fore blood sam ple collec tion. In formed con sent was ob tained from all the pa tients.
Non-adherent mononuclear cells isolation and IFN-b1a treat ment
Pe riph eral blood mononuclear cells (PBMC) were iso lated us ing a Ficoll-Hypaque den sity gra di ent. Cells from each sub ject were aliquoted into four frac tions: -Frac tion 1 "BASAL"; this sam ple was processed im me di ately to ob tain to tal RNA.
Two re com bi nant hu man in ter feron-beta 1a phar ma ceu ti cal prep a ra tions
The other three frac tions were sus pended at 10 6 cells/ml and in cu bated for 24 h in RPMI 1640 me dium with glutamine and 10% fe tal bo vine se rum, at 37 ºC in 5% CO 2 hu mid i fied at mo sphere, un der three con di tions: -Frac tion 2 "CON TROL"; sam ple with out IFN-b. -Frac tion 3 "BLASTOFERON"; sam ple with 1,000 IU/ml of Blastoferon ® prep ara tion. -Frac tion 4 "REBIF", sam ple with 1,000 IU/ml of Rebif ® prep a ra tion.
RNA amplification, labeling and microarray hybridization
Af ter 24 hours of cul ture, non-ad her ent cells (mostly lym pho cytes) were re cov ered, cen tri fuged, lysed and ho mog e nized. For each sam ple, to tal RNA was iso lated with the RNAeasy ® Mini Kit ex trac tion and pu ri fi cation sys tem (QIAGEN Inc., Va len cia, CA, USA) and an a lyzed for qual ity, in teg rity and DNA con tam i na tion by spectrophotometry and agarose gel elec tro pho re sis prior to cDNA syn the sis. CodeLink™ Ex pres sion Bioarray Sys tem was used for sam ple prep a ra tion and hy brid iza tion. To tal RNA (0.5 mg) from each sam ple was primed for re verse tran scrip tion with oligo-d(T) 24 con tain ing the T7 RNA poly mer ase pro moter site. Af ter sec ond-strand cDNA syn the sis, the dscDNA served as the tem plate for an in vi tro tran scrip tion (IVT) reac tion to pro duce the tar get cRNA. IVT was per formed by the lin ear am pli fi ca tion method in the pres ence of bi o tin-11-UTP to la bel the tar get cRNA (Perkin Elmer, Boston, MA, USA). Af ter frag men ta tion, 8 mg of cRNA and CodeLink™ Hu man Whole Ge nome Bioarray were hy brid ized over night at 37 ºC. The prearrayed 30-mer oligonucleotide slides contained over 45,000 well char ac ter ized hu man gene and tran scripts. La bel ing with Cy5-streptavi din was per formed and slides were scanned at 635 nm for 3.5 s with 4.5 mm pixel size res o lu tion in the arrayWoRx™ "e" scanner (Ap plied Pre ci sion, LLC, Issaquah, WA, USA). Im age anal y sis and raw data were assessed with CodeLink™ Ex pres sion Anal y sis Soft ware ver sion 4.1. Val ues ob tained were glob ally nor mal ized to the me dian ex pres sion value of the whole ar ray spots.
Bioinformatics and statistical data analysis
Raw data were im ported into R sta tis ti cal pro gram ming lan guage en vi ron ment, ver sion 2.3.01. Graphic and sta tis ti cal anal y sis was per formed us ing CodeLink and Lin ear Models for Microarray Data (LIMMA, 2.6.2) [Smyth 2005 ] pack ages in cluded in Bioconductor Pro ject [Dudoit et al. 2003 ]. The pre pro cess ing of the data sets to fil ter spots flagged as "bad", back ground cor rec tion and be tween microarrays nor mal iza tion was done with CodeLink package.
Log 2 Fold change and p-value of dif fer ential ex pres sion for each gene were ob tained per form ing the fol low ing com par i sons: -Blastoferon vs. Rebif = BLASTOFERON mi nus REBIF, i.e. dif fer en tial gene expres sion be tween both prod ucts. -IFN-b1a Ef fect = (BLASTOFERON plus REBIF) mi nus CON TROL mi nus BASAL, i.e. dif fer en tial gene ex pres sion due to IFN-b1a ef fect, ir re spec tive of phar maceu ti cal prep a ra tion used. -Blastoferon = BLASTOFERON mi nus CON TROL/2 mi nus BASAL/2, i.e. differ en tial gene ex pres sion due to Blastoferon ® prep a ra tion. -Rebif = REBIF mi nus CON TROL/2 minus BASAL/2, i.e. dif fer en tial gene expres sion due to Rebif ® prep a ra tion.
Dif fer en tially ex pressed genes were identi fied us ing an em pir i cal Bayes mod er ated t-test and ranked in or der of ev i dence for differ en tial ex pres sion with LIMMA. The empir i cal Bayes pro ce dure pro vides an ef fec tive frame work for study ing the rel a tive changes in gene ex pres sion for a large num ber of genes. It uses a sim ple non-para met ric mixture prior to model the pop u la tion of af fected and un af fected genes, thereby avoid ing paramet ric as sump tions about gene ex pres sion [Efron and Tibshirani 2002] . The p-val ues asso ci ated with the t-test were ad justed for multi ple test ing by us ing the Hochberg and Benjamini [1990] method. Thus, genes with an ad justed p-value lower than 0.05 were iden ti fied as dif fer en tially ex pressed.
Functional classification of differentially expressed genes
The rank ing of func tional cat e go ries based on co-oc cur rence with sets of genes included in a list (the dif fer en tially ex pressed genes in our case) was done us ing DA VID (Da ta base for An no ta tion, Vi su al iza tion and In te grated Dis cov ery) tool [Dennis et al. 2003 ].
Confirmation by real time RT-PCR
The ex pres sion of MX2, OAS2, GBP1 genes were in de pend ently quan ti fied by RT2 Real-Time® RT-PCR As says (SuperArray Bio sci ence Corp., Fred er ick, MD, USA) using the SYBR ® Green (Mo lec u lar Probes Inc., Eu gene, OR, USA) de tec tion method with high qualitiy gene-spe cific PCR primer sets and mas ter mixes for microarray data validation.
Results
Ta ble 1 shows that both prod ucts ("IFN-b Ef fect") dif fer en tially reg u lated the ex pression of 868 genes (p-value < 0.05). When Blastoferon ® and Rebif ® were com pared, none of the 45,000 well char ac ter ized hu man genes and tran scripts ex am ined, was dif fer entially ex pressed be tween them (min i mum p-value > 0.999). The ex pres sion lev els of selected genes (MX2, OAS2, and GBP1) were con firmed by means of real time RT-PCR assays (data not shown).
The func tional an no ta tion anal y sis of the IFN-b1a transcriptome showed an over-rep resen ta tion of the fol low ing classes: in ter feron re sponse, stress re sponse, in flam ma tory response, sig nal transduction, chemotaxis and cel lu lar com mu ni ca tion. To fur ther com pare Blastoferon ® and Rebif ® , an in de pend ent func tional an no ta tion anal y sis was done for the genes up-and down-reg u lated by each prod uct, re sult ing in an al most iden ti cal clus ter ing for Blastoferon ® and Rebif ® (Fig ure 1) .
As an ad di tional il lus tra tion of this sim ilar ity, the fold change re sponse of the 100 most sig nif i cant up-and down-reg u lated genes by both IFN-b1a phar ma ceu ti cal prepa ra tions is shown in Figure 2 : both prod ucts have al most superimposable gene stimula tion pat terns.
Two re com bi nant hu man in ter feron-beta 1a phar ma ceu ti cal prep a ra tions 67 Ta ble 1. Quan ti ta tive dis tri bu tion of the genes dif fer en tially ex pressed by IFN-b1a. The high de gree of sim i lar ity (min i mum ad justed p-value > 0.999) is also shown by the box and whis kers plot of the ex pres sion lev els of some spe cific genes re lated to in ter feron ac tion (Fig ure 3) . More over, when genes differ en tially ex pressed by IFN-b were an a lyzed us ing hi er ar chi cal clus ter ing, both prod ucts were clus tered to gether in each pa tient (Figure 4) . 
Discussion
Data herein show that, un der these ex per imen tal con di tions, the two as sessed phar maceu ti cal prep a ra tions of IFN-b1a re sulted in a sim i lar transcriptional reg u la tion in mononuclear leu ko cytes in pa tients with MS. This find ing was made pos si ble by us ing the power ful whole ge nome micro array anal y sis.
Al though there are sev eral short com ings in this study (some re lated to the method we se lected and some to the de sign), none of them hin ders an ap pro pri ate com par i son between both prod ucts. The most re cent eval u ation from the MicroArray Qual ity Con trol pro ject re vealed that the bioarray plat form that we have used has higher lev els of sen sitiv ity rel a tive to the other microarray platforms as sessed [Patterson et al. 2006 , Shi et al. 2006 . It de tects nearly 30% more genes, in clud ing as much as 60% more of the low est ex pressed genes, with con cen tra tions as low as 50 fM, when com pared to other com mercial microarray plat forms. De tec tion sen si tivity of microarrays is a key per for mance at tribute to sup port ex pan sion of genomics into clin i cal ap pli ca tions. A pre vi ous com par i son of 6 dif fer ent microarray plat forms con cluded that high-qual ity ar rays and appropriate analy sis de ter mine bi o log i cal rather than tech nolog i cal vari ance [Yau k et al. 2004] . Microarrays have been used for the study of MS pathophysiology and re sponse to treat ment [Comabella and Mar tin 2007] and are con sidered among the most pow er ful tech niques for drug dis cov ery [Stoughton and Friend 2005] .
Short com ings of the de sign in clude the size and cell type of the sam ple, the dose of IFN-b1a and the du ra tion of the cell cul ture. Though the num ber of pa tients in cluded in the study is small, each in di vid ual is act ing as its own con trol, thereby re duc ing het er o ge ne ity and max i miz ing power. Even though the eval u a tion of lym pho cyte tran scrip tion lev els might pro vide in com plete ge nome screen ing re sults in terms of such a com plex CNS pathol ogy as MS, this cell type stands as the only eth i cally avail able for in vi tro stud ies and has been thor oughly used as a com mon model for MS studies [Satoh et al. 2006a] .
As to the du ra tion of the cul ture, 24 hours was se lected since it is a very com mon in cuba tion time in most pre vi ous stud ies with microarray anal y ses of IFN-b ef fect [Weinstock-Guttman et al. 2003 ]. Fi nally, the dose was se lected to de tect most IFN-b re lated effect. We can not ex clude dif fer ences at lower lev els of IFN-b or in cu ba tion times, al though this pos si bil ity does not seem very probable.
The study was de signed to com pare two sim i lar IFN-b1a for mu la tions. Since this cytokine is a transcriptional reg u la tor and is used to treat MS pa tients, a crit i cal is sue was the se lec tion of the genes to be tested. Currently, no clear ex pla na tion for IFN-b ef fect in MS is avail able, so, whole ge nome as say was se lected. In ad di tion, ge netic fac tors are in volved in the pathophysiology of MS [Hauser and Oksenberg 2006] ; to de crease the risk of loos ing sig nif i cant genes pres ent or reg u lated dif fer en tially be tween healthy subjects and MS pa tients, we per formed the study on leukocytes of patients in vitro.
For con ven tional ge neric prod ucts, the ratio nale for com par i son with in no va tor products is that if equiv a lent con cen tra tions of the same mol e cule are achieved with both products, then sim i lar re sponses should be expected. For biosimilars, reg u la tory au thor ities, such as EMEA, have pro duced spe cific guide lines to deal with dif fer ences orig i nated in the cell lines from which the biosimilar is ob tained or in the man u fac tur ing pro cess. Since for IFN-b a di rect mea sure of re sponse is dif fi cult to ob tain and im plies ex po sure of large numbers of peo ple to ex per i men tal condi tions, an al ter na tive ap proach can be the detec tion of the re sponse by rel e vant effector cells, com bined with a for mal study of rel ative bioavailability. In this re port we have shown that mononuclear leu ko cytes of MS pa tients are un able to dif fer en ti ate be tween Blastoferon ® and Rebif ® un der the ex perimental con di tions used.
As a con se quence of the re cent ex pi ra tion of some pat ents, there is a grow ing need of reli able tests in or der to ad dress com pa ra bil ity of bi o log i cal re sponse to biosimilar phar maceu ti cal prod ucts [Roger 2006 ]. Pre vi ous stud ies re port ing the genomic ef fects of IFN-b in the treat ment of MS pa tients have been per formed, but none of them com pared the ef fects of two biosimilar prod ucts. In deed the only com par a tive stud ies with IFN-b1a were based on pharmacokinetic pa ram e ters [Munafo et al. 1998 ] or clin i cal end points [Panitch et al. 2002] . While both de signs are clas sic and per ti nent, they prob a bly lack the abil ity to de tect mi nor dif fer ences and their re sults might be par tial and con tro ver sial [Rogge et al. 1999] . Our study is an ex am ple that microarray technology could become a useful tool for comparability studies.
Al though a de tailed anal y sis of IFN-b1a ef fect in this ex per i ment is un der way (Kauffman et al., manu script in prep a ra tion), well rec og nized IFN-b re lated genes were iden ti fied among the top fold-change ranked genes. In agree ment with pre vi ous stud ies [Baranzini et al. 2005 , Buttmann et al. 2006 , Satoh et al. 2006b , Sturzebecher et al. 2003 ] our re sults show the up-reg u la tion of TRAIL (Tu mor Ne cro sis Fac tor Superfamily, Member 10), Mx1 (Myxovirus Re sis tance 1), Mx2 (Myxovirus Re sis tance 2), CXCL10 and 11 (Chemokine C-X-C-Mo tif Lig ands 10 and 11), STAT1 (Sig nal Trans ducer and Ac ti va tor of Tran scrip tion 1), IRF-7 (In ter feron Reg ula tory Fac tor 7), AIM2 (Ab sent in Mel a noma 2), OAS2 (2'-5'-oligoadenylate synthetase 2, 69/71 kD) and GBP1 (Guanylate Bind ing Pro tein 1) and the down-reg u la tion of ITGAM (Integrin al pha M), IL1B (Interleukin-1b) and NRG1 (Neuroregulin 1).
In con clu sion, we have in ves ti gated the in vi tro pharmacodynamic genomic ef fects of IFN-b1a treat ment on a whole ge nome microarray as say on lym pho cytes from MS pa tients com par ing the sim i lar ity be tween two bi o logi cal prod ucts man u fac tured by two phar maceu ti cal com pa nies. This ex haus tive and highly sen si tive as say did not show dif ferences in the genomic ex pres sion pro file of these two prod ucts un der the as sayed ex per imen tal con di tions. Since no dif fer ence in genomic ex pres sion un der ex per i men tal condi tions does not nec es sar ily re sult in clin i cal safety and efficacy, further studies are required to assess these issues.
